Seattle Genetics, Merck partner on 2 oncology drug programs

By The Science Advisory Board staff writers

September 14, 2020 -- Seattle Genetics and Merck will collaborate to develop and commercialize Seattle Genetics' ladiratuzumab vedotin, an antibody-drug conjugate (ADC). Separately, Seattle Genetics has granted Merck an exclusive license to commercialize a small-molecule drug for treatment of HER2-positive cancers.

Together, the companies will develop and commercialize ladiratuzumab vedotin, an investigational ADC targeting LIV-1, which is in phase II clinical trials for breast cancer and other solid tumors. Joint development will evaluate the ADC as a monotherapy and in combination with Keytruda, Merck's anti-PD-1 therapy, in triple-negative breast cancer and other solid tumors.

Seattle Genetics will receive a $600 million upfront payment and Merck will make a $1 billion equity investment in 5 million shares of Seattle Genetics at a price of $200 per share. Seattle Genetics will also be eligible for progress-dependent milestone payments of up to $2.6 billion.

Merck will commercialize tucatinib (Tukysa), a small-molecule tyrosine kinase inhibitor for the treatment of HER2-positive cancers, in Asia, the Middle East, and Latin America and other regions outside of the U.S., Canada, and Europe. Seattle Genetics will receive an upfront payment of $125 million from Merck and is eligible for progress-dependent milestones of up to $65 million. Merck will also co-fund global development efforts, including several ongoing and planned clinical trials. Seattle Genetics will continue to lead these projects.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here